ENGN

enGene Holdings Inc

enGene Therapeutics Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene) in high-risk...

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totaling 1,330,981 shares, an increase of 16.2% from the March 31st total of 1,145,907 shares. Based on an average daily volume of 199,435...

Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven research firms that are currently covering the stock, Marketbeat...

Wall Street Zen lowered shares of enGene from a "hold" rating to a "sell" rating in a research report on Saturday...

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totaling 1,145,907 shares, a growth of 24.2% from the March 15th total of 922,661 shares. Based on an average daily trading volume...

WBB Securities began coverage on enGene in a research note on Monday. They issued a "buy" rating and a $21.50 price objective for the company...

enGene (NASDAQ:ENGN) Stock Price Up 5.2% - Here's What Happened...

enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its...

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 922,661...